153 related articles for article (PubMed ID: 38454119)
1. There's life in the old dog yet: immunochemotherapy in Waldenström's macroglobulinemia.
Kastritis E; Buske C
Leukemia; 2024 Jun; 38(6):1435-1436. PubMed ID: 38454119
[No Abstract] [Full Text] [Related]
2. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
[No Abstract] [Full Text] [Related]
3. Waldenström's macroglobulinemia.
Cuttner J
Cancer Invest; 1991; 9(1):107. PubMed ID: 1901510
[No Abstract] [Full Text] [Related]
4. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of Waldenstrom's macroglobulinemia: 4 case reports].
Lu SF; Chen XW; Lin TB
Zhonghua Nei Ke Za Zhi; 1985 Jun; 24(6):358-9, 382-3. PubMed ID: 3926417
[No Abstract] [Full Text] [Related]
6. Metronomic chemoimmunotherapy in a patient with refractory Waldenstrom's macroglobulinemia.
Fassas AB; Kiwan E; Roberts J; Burr T; Tricot G; Anaissie E; Barlogie B
Leuk Lymphoma; 2005 Nov; 46(11):1675-7. PubMed ID: 16334910
[No Abstract] [Full Text] [Related]
7. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
8. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
10. Endobronchial involvement with Waldenström's macroglobulinemia.
Sakai I; Shiroguchi T; Kanegae H; Matumoto I
Intern Med; 1992 Sep; 31(9):1098-101. PubMed ID: 1421716
[TBL] [Abstract][Full Text] [Related]
11. How to manage waldenström's macroglobulinemia in 2024.
Grunenberg A; Buske C
Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
13. [Meningeal lymphomatosis as late relapse of Waldenstrom's macroglobulinemia].
Alonso Alonso JJ; Cánovas Fernández A; Fernández Martínez M; Pérez Garay R
Med Clin (Barc); 2016 Feb; 146(3):141. PubMed ID: 26243251
[No Abstract] [Full Text] [Related]
14. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment.
Buske C; Seymour JF
Leuk Lymphoma; 2015; 56(9):2489-90. PubMed ID: 26054374
[No Abstract] [Full Text] [Related]
16. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
17. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
18. Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Eulitt P; Fabian D; Kelly C; Hemminger J; William BM
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):54-59. PubMed ID: 28390215
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
